A research team led by Purdue University's W. Andy Tao has discovered a new type of protein modification related to cellular mutation that impairs a crucial enzyme's ability to help drive energy ...

Arthropod-borne viruses (arboviruses), such as dengue and Zika viruses, transmit widely across the globe, posing threats to human health and biosecurity. They spread through the bites of arthropod ...

The likelihood of EGFR-positive lung cancer returning is largely tied to how advanced it is when first diagnosed, with lower chances in early stages and higher odds in later stages. Newer targeted ...

Patients with stage 4 lung cancer and EGFR mutations may benefit from combination therapies that improve disease control. The American Society of Clinical Oncology (ASCO) released updated treatment ...

EGFR-positive lung cancer is more common in non-smokers (particularly those with adenocarcinoma) and younger adults, as it often develops from a single genetic mutation rather than widespread DNA ...

At its December meeting, the European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use adopted a positive opinion for Aumseqa (aumolertinib mesylate, SFL Pharmaceuticals ...

Emerging research highlights the transformative potential of m6A RNA modification in the diagnosis and treatment of cardiovascular diseases (CVDs). As the most abundant internal modification of ...

Please provide your email address to receive an email when new articles are posted on . One-third of Black candidates had a wait-time modification under new policy of race-neutral eGFR assessment.

Sunvozertinib showed efficacy in NSCLC with EGFR exon 20 insertion mutations, with ORRs around 46% across dosing cohorts. Higher response rates were observed in patients with brain metastases and ...

BERLIN -- An antibody-drug conjugate targeting Trop2 significantly improved survival outcomes compared with platinum-based chemotherapy in pretreated patients with EGFR-mutated non-small cell lung ...